Amphista Therapeutics Appoints Dr Martin Pass as CDO

Cambridge, England, 6 December 2021 – Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the appointment of Dr Martin Pass, as Chief Development Officer (CDO).

Read the full release here.